Soleno Therapeutics Down Over 29%, on Pace for Largest Percent Decrease Since March 2021 -- Data Talk

Dow Jones11-06

Soleno Therapeutics Inc ( SLNO ) is currently at $45.16, down $18.70 or 29.28%

 

--Would be lowest close since March 11, 2025, when it closed at $44.78

--On pace for largest percent decrease since March 8, 2021, when it fell 48.7%

--Currently down five consecutive days; down 35.45% over this period

--Longest losing streak since Sept. 16, 2025, when it fell for six straight trading days

--Worst five day stretch since the five days ending March 12, 2021, when it fell 42.75%

--Up 0.46% year-to-date

--Down 93.12% from its all-time closing high of $656.25 on March 4, 2015

--Down 20.59% from 52 weeks ago (Nov. 6, 2024), when it closed at $56.86

--Down 48.97% from its 52-week closing high of $88.49 on July 9, 2025

--Up 6.15% from its 52-week closing low of $42.54 on Jan. 14, 2025

--Traded as low as $43.89; lowest intraday level since March 11, 2025, when it hit $43.00

--Down 31.26% at today's intraday low; largest intraday percent decrease since March 8, 2021, when it fell as much as 49.83%

 

All data as of 11:39:24 AM ET

 

Source: Dow Jones Market Data, FactSet

 

(END) Dow Jones Newswires

November 05, 2025 11:46 ET (16:46 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment